Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026 Abbott announced novel late-breaking data from four clinical trials demonstrating strong outcomes for its pulsed field ablation and conduction system pacing technologies at Heart Rhythm Society 2026 in Chicago. The findings support the company’s growing portfolio designed to treat a wide range of heart rhythm disorders. Six-month results from the FlexPulse IDE study showed positive patient outcomes with the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, for treating complex atrial fibrillation cases. Abbott noted the data confirmed the strong safety and efficacy profile previously observed in its FOCALFLEX CE mark study. The TactiFlex Duo system is a dual-energy, focal ablation catheter that allows physicians to customize how they deliver atrial fibrillation therapy using radiofrequency energy to destroy tissue responsible for erratic heart signals. New clinical evidence from the Volt CE Mark Extension Cohort trial demonstrated the strong safety, efficacy, and efficiency of the Volt™ PFA System for posterior wall ablation in atrial fibrillation cases. The system uses pulsed field ablation technology to treat abnormal heart tissue with precise electrical fields. Abbott likewise shared initial results from the ASCEND CSP IDE trial evaluating its investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead. The company revealed a first-in-human evaluation of its investigational AVEIR™ CSP leadless pacemaker system from the LEAP2 chronic early feasibility trial. According to Priya Jagasia, divisional vice president of regulatory, clinical, reimbursement and strategic initiatives at Abbott, treating abnormal heart rhythms requires a comprehensive approach. “Treating abnormal heart rhythms is not a siloed or one-size-fits-all approach, which is why Abbott is creating a holistic cardiovascular portfolio that empowers physicians to care for a wide range of arrhythmias,” Jagasia stated. “The data from these clinical trials serve as a cornerstone for the new innovations we’re developing to help people live healthier lives.” The presentations were part of Abbott’s broader effort to showcase the strength of its technologies in addressing abnormal heart rhythms through late-breaking clinical data at Heart Rhythm Society 2026.
8